FDA Approves BioLineRx's APHEXDA (motixafortide) in Combination with Filgrastim) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved BioLineRx's APHEXDA (motixafortide) in combination with Filgrastim for the mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
September 11, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLineRx's APHEXDA has received FDA approval, which could potentially increase the company's market share and revenues.
FDA approval is a significant milestone for any pharmaceutical company. It opens up the market for the approved drug, potentially leading to increased sales and revenues. Given that BioLineRx's APHEXDA has been approved, it is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100